American Healthcare REIT, Inc. (AHR): what the price requires

At today's price, American Healthcare REIT, Inc. (AHR) is priced for today's economics sustained for ~7.8 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/AHR

Headline

FieldValue
TickerAHR
CompanyAmerican Healthcare REIT, Inc.
Current price$54.29/sh
CompositionIntegrated Senior Health Campuses (ISHC) 78% / Senior Housing Operating Properties (SHOP) 15% / Outpatient Medical (OM) 6% / Triple-Net Leased Properties 2%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basisreit
Top-of-range FFO growth must hold for7.8y
Price-to-FFO34.0x
FFO yield2.9%

Solve inputs: computed at a 8.8% cost of equity; growth searched up to the 15% ceiling; each 1pp moves the implied horizon ~2.9 years.

How unusual the bet is: extreme

ReferenceValue
vs own history-0.36σ
cohort percentile (of 88 peers)99
sustained it ~7.8 years at this level55%
implied end-window share0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset10.19x4expensive
Earnings3.98x5expensive
Relative1.60x6expensive
Growth0.78x3justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.6%); the inversion above states its own rate.

Per-Model Detail (n=18)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$73.190.74xyesFCF base $0.4B, growth 23% (input: historical growth), terminal g 4.0%, WACC 8.6%, 7yr projection
DCF Exit MultipleGrowth$70.040.78xyesExit EV/EBITDA: 14.7x / 16.7x / 18.7x (bear / base = today's held flat / bull), 7yr
Relative ValuationRelative$62.780.86xyesP/E 35x (static sector reference · 2026-04), scenarios: 28.4x / 35.0x / 41.6x (bear / base = reference held flat / bull), EV/EBITDA 20x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$5.779.41xyesBV/sh $18.52, ROE (TTM) 2.9%, ke 9.3%
Two-Stage Excess ReturnAsset$3.4215.87xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$66.630.81xyesRev $2.4B, growth 23% (input: historical growth; tapered), Terminal P/S: 3.5x / 4.3x / 5.1x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair ValueRelative$19.562.78xyesFFO/share $1.63, growth 5% (input: historical FFO/share growth, 6y median), PEG=21.78 (Overvalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$12.124.48xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.34B × (1−21%) / WACC 8.6% → EPV (no growth)
Residual IncomeAsset$2.5321.46xyesBV $18.52 + 5yr PV of (ROE (TTM) 2.9% − Kₑ 9.3%) × BV; BV grows 1.9%/yr (excluded from median)
Graham NumberAsset$26.062.08xyes√(22.5 × FFO/share $1.63 × BVPS $18.52) — Graham's conservative floor
EV/EBITDA RelativeRelative$65.700.83xyesEBITDA $0.66B × sector EV/EBITDA 20.0x
FCF YieldEarnings$13.633.98xyesFCF $314.9M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$12.654.29xyesSBC-adj FCF $0.30B (FCF $0.31B − SBC $0.02B) capitalized at Kₑ
Ben Graham FormulaEarnings$24.372.23xyesFFO/share $1.63 × (8.5 + 2×4.7%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$4.9510.97xyesBV $18.52 × (ROIC 2.3% / WACC 8.6%)
P/Sales SectorRelative$75.660.72xyesRevenue $2.37B × sector P/S 6.0x
PEG Fair ValueRelative$11.424.75xyesFFO/share $1.63 × (PEG 1.5 × growth 4.7% (input: historical FFO/share growth, 6y median)) → PE 7.0x
Earnings YieldEarnings$17.623.08xyesFFO/share $1.63 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative$23.182.34xyesFFO/share $1.63 × 14.2x P/FFO (route cohort median, n=85); FFO $0.31B (FFO incl. D&A + impairments, FY2025, companyfacts), shares 188M
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Fixed-charge coverage (FFO basis)4.6x
Funds from operations (trailing)$307.3m
Share count CAGR (dilution)30.1%
Burning cashno

REIT basis: leverage is read against funds from operations (FFO), not depreciation-gutted operating income. The header's implied growth runs on ADJUSTED FFO — FFO minus recurring maintenance capex — so the header's multiple and this leverage ratio use bases that differ by that capex; neither substitutes for the other. Net debt could not be resolved from the corporate debt tags in the filings (REIT notes and mortgage debt are often tagged outside the corporate ladder), so the leverage ratio is withheld rather than rendered from incomplete tags.

Bullet Takeaways

Normalized funds from operations grew fast: first-quarter 2026 came in at $0.50 per diluted share, up 31.6 percent from $0.38, and management raised full-year guidance to $2.09 to $2.30, targeting roughly 20 percent growth.

At $46.55 the trust trades near 37 times adjusted funds from operations, the very top of the REIT group. The price embeds top-of-range growth sustained for about six years, the most demanding end of the scale.

The engine is the operating senior-housing portfolio, where the trust keeps the upside through RIDEA structures. That same structure is what makes the cash flow swing with occupancy, labor cost and the operators, chiefly Trilogy, who run the buildings.

Bull Case

The earnings trajectory is the case, and it has been steep. American Healthcare REIT reported first-quarter 2026 normalized funds from operations of $0.50 per diluted share, up 31.6 percent from $0.38 a year earlier, and raised full-year 2026 guidance to $2.09 to $2.30 per share, a target of roughly 20 percent growth over 2025. The same-store net operating income guide was lifted to 9 to 12 percent in total, led by 15 to 19 percent in the senior housing operating portfolio and 11 to 15 percent at Trilogy, the integrated senior health campuses that make up the bulk of the business. For a healthcare REIT, those are unusually high internal growth rates, and they are coming through in the reported cash earnings.

The structure of the portfolio is what lets the growth flow to shareholders. The trust runs its senior housing through RIDEA arrangements, and the filing is explicit that those facilities are "operated utilizing RIDEA structures, allowing us to participate in the upside from any improved" operating performance (FY2025 10-K, accession 0001193125-26-082692). Where a triple-net landlord collects a fixed rent, AHR captures the operating recovery directly as senior-housing occupancy and rates climb off the pandemic trough and the aging demographic tailwind builds. The integrated campuses and outpatient medical assets add a steadier base underneath the operating leverage.

Management is pressing the advantage with external growth on top of the internal engine. The company closed $249.2 million of senior housing operating acquisitions and pointed to a roughly $650 million pipeline, primarily with existing operating partners it already knows. The fixed-charge coverage near 4.8 times indicates the cash flow comfortably services the financing even as the trust raises capital to fund the pipeline. With internal NOI growth running double digits, an acquisition pipeline anchored to known operators, and a demographic wave still ahead, the trust has the kind of forward growth profile that the static, depreciation-burdened valuation frames cannot fully credit.

Bear Case

The bear case is that the price already assumes the best of this continues for years, and the model that produces the growth is the same one that can take it away. At $46.55 (June 27, 2026) the trust trades near 37 times adjusted funds from operations, the very top of the REIT group, and inverting that multiple implies top-of-range AFFO growth sustained for roughly six years. Historically only about 55 percent of REITs growing at that pace held it that long. The narrative the price depends on, double-digit same-store growth far above what a normal healthcare REIT delivers, has to keep printing, because at this multiple a deceleration to ordinary REIT growth would re-rate the stock toward where the asset and earnings methods sit, near the mid-thirties.

The RIDEA structure cuts both ways, and that is the specific dependency. The same arrangement that lets the trust keep the upside also exposes it directly to operating costs, occupancy swings, and labor, with no fixed rent to cushion a downturn. Senior-housing operating cash flow is volatile, and a soft occupancy cycle or a wage-inflation spike flows straight to NFFO. Layered on top is operator concentration: the filing states that "all of our ISHC are managed by Trilogy Management Services, LLC, or the Trilogy Manager, and account for a significa" portion of the portfolio (FY2025 10-K, accession 0001193125-26-082692). The integrated campuses are roughly three-quarters of the business and run by a single manager, so the growth story is also a single-operator story.

The growth has been funded with equity, and that has a cost. The share count has expanded sharply as the trust raised capital to close acquisitions, so per-share NFFO growth has to outrun the dilution to reward holders, and external deals must be accretive net of the new shares. The trust also carries meaningful financing, with senior unsecured term loan facilities reported around $689 million (same filing), and the leverage on REIT notes and mortgage debt is large enough that the corporate debt tags do not even resolve a clean net-debt figure. A REIT priced at the top of its group, dependent on volatile operator cash flow, a single manager, and continued accretive equity-funded M&A, has little room for any one of those to disappoint.

Valuation

A real-estate trust is valued on its adjusted funds from operations, the cash earnings plus property depreciation minus the recurring maintenance capex that keeps the buildings leasable, not on an operating multiple. On that basis the price is justified only by the relative-multiple and forward-growth frames; the asset-based and earnings-power methods read the stock as expensive, and the blended central value across methods sits near $34 against the $46.55 price.

The gap is the growth assumption, and here it is at the demanding end. At about 37 times adjusted funds from operations, the price-to-AFFO sits at the very top of the REIT group, and inverting it implies the trust grows AFFO at the top of the REIT range for roughly six years. The assumed pace is within what AHR has recently delivered, given first-quarter 2026 NFFO of $0.50 per share, up 31.6 percent, and full-year guidance of $2.09 to $2.30, so the rate is credible off the current base. The stretch is the duration and the multiple: only about 55 percent of REITs growing this fast sustained it across a window this long, and the stock pays a premium to every peer for the privilege. The investment question is therefore not whether AHR is growing, it plainly is, but whether the senior-housing operating recovery and the acquisition pipeline can hold double-digit internal growth long enough to justify a top-of-group multiple, while the RIDEA cash flows stay strong and the equity-funded deals stay accretive. The reward is real if the runway holds; the risk is that a top-tier multiple leaves no margin if growth normalizes early.

Catalysts

Same-store NOI and NFFO guidance are the central catalysts. Management raised the 2026 same-store NOI target to 9 to 12 percent in total, with 15 to 19 percent in the senior housing operating portfolio and 11 to 15 percent at Trilogy, and lifted full-year NFFO guidance to $2.09 to $2.30 per share. Each quarter is a check on whether occupancy and rate gains in the operating portfolio keep delivering those rates, since the top-of-group multiple is paying for exactly that. First-quarter NFFO of $0.50, up 31.6 percent, set the early pace.

External growth is the second catalyst. The company closed $249.2 million of senior housing operating acquisitions and pointed to a roughly $650 million pipeline, primarily with existing operating partners. Watch the pace and pricing of those closings and, just as important, how they are funded, because equity-funded deals must be accretive net of new shares to grow per-share NFFO. Announced acquisitions and any equity raises are the events to track.

Operating costs and occupancy are the swing factors to monitor. Because the senior housing portfolio runs on RIDEA structures, labor inflation, staffing availability, and occupancy trends feed straight into cash flow. A wage spike or an occupancy stall would pressure the very growth rates the guidance assumes, while continued post-pandemic occupancy recovery and demographic demand would support them. Quarterly results remain the main proof point on whether the double-digit internal growth is holding.

Peer Cohorts (Per Segment, With Filing Citations)

Integrated Senior Health Campuses (ISHC) (reported)

Senior Housing Operating Properties (SHOP) (reported)

Outpatient Medical (OM) (reported)

Triple-Net Leased Properties (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

View the full interactive AHR report on boothcheck